Format

Send to

Choose Destination
Endocrine. 2016 Feb;51(2):205-10. doi: 10.1007/s12020-015-0727-2. Epub 2015 Sep 4.

Treating prolactinomas with dopamine agonists: always worth the gamble?

Author information

1
Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
2
Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK. vickystokes22@hotmail.com.

Abstract

Dopamine agonists are the treatment of choice for all patients with prolactinomas. They are generally safe, effective, and well-tolerated. However, a link between their use and the development of impulse control disorders has been well recognized in the field of neurology for some time, and evidence for a similar effect in endocrine patients is emerging. This has mainly been revealed through clinical case reports, plus a small number of comparative studies of varying robustness. We review the current available literature and discuss the implications for clinical practice, in particular emphasizing the need for clinicians to be alert to these uncommon but serious adverse effects.

KEYWORDS:

Bromocriptine; Cabergoline; Gambling; Hypersexuality; Impulse control

PMID:
26336835
DOI:
10.1007/s12020-015-0727-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center